Monte Rosa Therapeutics (GLUE) Looks Pricey As Phase 2 Progress Keeps The Story Alive

Monte Rosa Therapeutics (GLUE) dosed the first patient in its MODeFIRe-1 Phase 2 trial of MRT-2359 with apalutamide for AR mutation-positive metastatic castration-resistant prostate cancer, building on earlier combination data with enzalutamide.

See our latest analysis for Monte Rosa Therapeutics.

The MRT-2359 update comes after a sharp 36.08% decline in the 30-day share price return and a 24.05% decline over 90 days, even as the 1-year total shareholder return of 211.78% and 3-year total shareholder return of 131.11% point to strong longer term gains.

If this kind of clinical progress has your attention, it could be a good moment to look across the sector using our healthcare focused AI stocks screener, starting with 42 healthcare AI stocks.

Monte Rosa Therapeutics has a clinically active pipeline and a share price that has swung sharply in both directions. After this latest move, is the business strength already reflected in the current US$14.56 valuation, or not?

Preferred Price-to-Sales Multiple of 43.2x: Is it justified?

On a simple sales-based yardstick, Monte Rosa Therapeutics looks expensive. The stock trades at a P/S of 43.2x at a last close of $14.56, while peers sit at much lower levels.

The P/S ratio compares the company’s market value to its revenue. For a clinical-stage biotech like Monte Rosa Therapeutics with US$28.7m in revenue and no profits yet, investors often use this multiple because earnings are still negative.

At 43.2x sales, Monte Rosa Therapeutics is priced well above both its direct peers, which average 7.7x, and the broader US Biotechs industry at 13.3x. The company also scores 1 out of 6 on the internal value score, and its current P/S is far above the estimated fair P/S of 0x. This implies a valuation that could have a long way to compress if sentiment or expectations cool.

Explore the SWS fair ratio for Monte Rosa Therapeutics

Result: Price-to-sales of 43.2x (OVERVALUED)

However, Monte Rosa Therapeutics still faces key risks, including clinical trial setbacks for MRT-2359 and ongoing losses from net income of US$161.1m, which could pressure sentiment.

Find out about the key risks to this Monte Rosa Therapeutics narrative.

Next Steps

Given the mix of enthusiasm and caution around Monte Rosa Therapeutics, it helps to move quickly and test the data against your own expectations. To see how the risk warnings stack up against the potential rewards before forming a view, take a close look at the 2 key rewards and 5 important warning signs

Looking for more Monte Rosa Therapeutics investment ideas?

Broadening your watchlist beyond Monte Rosa Therapeutics can help you spot opportunities that match your risk comfort and return goals while this stock story continues to play out.

• Target potential mispricings by scanning a curated set of quality opportunities through the 49 high quality undervalued stocks.
• Build a foundation of stability and income by focusing on companies highlighted in the 12 dividend fortresses.
• Reduce surprises in your portfolio by concentrating on resilient businesses featured in the 74 resilient stocks with low risk scores.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com